Description

A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants with Gout.

Gout is one of the most common types of inflammatory arthritis and is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, which are caused by the deposition of urate (uric acid) crystals in the joints. The most important risk factor for the development of gout is chronically elevated levels of uric acid in the blood; treatment of gout is focused on decreasing levels of uric acid.

The study will last approximately 34 weeks (about 8 months) for each subject, and subject will need to come to the study center up to 17 times.